Cargando…
Screening for MicroRNA combination with engineered exosomes as a new tool against osteosarcoma in elderly patients
The most common primary malignant bone sarcoma is Osteogenic sarcoma (OS) which has a bimodal age distribution. Unfortunately, the treatment of OS was less effective for elderly patients than for younger ones. The study aimed to explore a new microRNA (miRNA) which can bind to combining engineered e...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760984/ https://www.ncbi.nlm.nih.gov/pubmed/36545680 http://dx.doi.org/10.3389/fbioe.2022.1052252 |
_version_ | 1784852606084972544 |
---|---|
author | Han, Jiyu Zhao, Zitong Wang, Yanhong Yu, Tao Wan, Daqian |
author_facet | Han, Jiyu Zhao, Zitong Wang, Yanhong Yu, Tao Wan, Daqian |
author_sort | Han, Jiyu |
collection | PubMed |
description | The most common primary malignant bone sarcoma is Osteogenic sarcoma (OS) which has a bimodal age distribution. Unfortunately, the treatment of OS was less effective for elderly patients than for younger ones. The study aimed to explore a new microRNA (miRNA) which can bind to combining engineered exosomes for treatment of older OS patients. Based on GSE65071 and miRNet 2.0, two up-regulated miRNAs (miR-328, miR-107) and seven down-regulated miRNAs (miR-133b, miR-206, miR-1-3p, miR-133a, miR-449a, miR-181daysay, miR-134) were selected. Next, we used FunRich software to predict the up-stream transcription factors (TFs) of differentially expressed miRNAs (DE-miRNAs). By comparing target genes predicted from DE-miRNAs with differentially expressed genes, we identified 12 down-regulated and 310 up-regulated mRNAs. For KEGG analysis, the most enriched KEGG pathway was Cell cycle, Spliceosome, and Protein digestion and absorption. By using protein-protein interactions network, topological analysis algorithm and GEPIA database, miR-449a /CCNB1 axis was identified. Experiments in vitro were conducted to confirm the results too. MiRNA-449a is down-regulated in osteosarcoma and suppresses cell proliferation by targeting CCNB1. Our findings not only reveal a novel mechanism of miR-449a /CCNB1 in OS but also had laid the groundwork for further investigation and analysis in the field of exosome engineering. |
format | Online Article Text |
id | pubmed-9760984 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97609842022-12-20 Screening for MicroRNA combination with engineered exosomes as a new tool against osteosarcoma in elderly patients Han, Jiyu Zhao, Zitong Wang, Yanhong Yu, Tao Wan, Daqian Front Bioeng Biotechnol Bioengineering and Biotechnology The most common primary malignant bone sarcoma is Osteogenic sarcoma (OS) which has a bimodal age distribution. Unfortunately, the treatment of OS was less effective for elderly patients than for younger ones. The study aimed to explore a new microRNA (miRNA) which can bind to combining engineered exosomes for treatment of older OS patients. Based on GSE65071 and miRNet 2.0, two up-regulated miRNAs (miR-328, miR-107) and seven down-regulated miRNAs (miR-133b, miR-206, miR-1-3p, miR-133a, miR-449a, miR-181daysay, miR-134) were selected. Next, we used FunRich software to predict the up-stream transcription factors (TFs) of differentially expressed miRNAs (DE-miRNAs). By comparing target genes predicted from DE-miRNAs with differentially expressed genes, we identified 12 down-regulated and 310 up-regulated mRNAs. For KEGG analysis, the most enriched KEGG pathway was Cell cycle, Spliceosome, and Protein digestion and absorption. By using protein-protein interactions network, topological analysis algorithm and GEPIA database, miR-449a /CCNB1 axis was identified. Experiments in vitro were conducted to confirm the results too. MiRNA-449a is down-regulated in osteosarcoma and suppresses cell proliferation by targeting CCNB1. Our findings not only reveal a novel mechanism of miR-449a /CCNB1 in OS but also had laid the groundwork for further investigation and analysis in the field of exosome engineering. Frontiers Media S.A. 2022-12-05 /pmc/articles/PMC9760984/ /pubmed/36545680 http://dx.doi.org/10.3389/fbioe.2022.1052252 Text en Copyright © 2022 Han, Zhao, Wang, Yu and Wan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Bioengineering and Biotechnology Han, Jiyu Zhao, Zitong Wang, Yanhong Yu, Tao Wan, Daqian Screening for MicroRNA combination with engineered exosomes as a new tool against osteosarcoma in elderly patients |
title | Screening for MicroRNA combination with engineered exosomes as a new tool against osteosarcoma in elderly patients |
title_full | Screening for MicroRNA combination with engineered exosomes as a new tool against osteosarcoma in elderly patients |
title_fullStr | Screening for MicroRNA combination with engineered exosomes as a new tool against osteosarcoma in elderly patients |
title_full_unstemmed | Screening for MicroRNA combination with engineered exosomes as a new tool against osteosarcoma in elderly patients |
title_short | Screening for MicroRNA combination with engineered exosomes as a new tool against osteosarcoma in elderly patients |
title_sort | screening for microrna combination with engineered exosomes as a new tool against osteosarcoma in elderly patients |
topic | Bioengineering and Biotechnology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760984/ https://www.ncbi.nlm.nih.gov/pubmed/36545680 http://dx.doi.org/10.3389/fbioe.2022.1052252 |
work_keys_str_mv | AT hanjiyu screeningformicrornacombinationwithengineeredexosomesasanewtoolagainstosteosarcomainelderlypatients AT zhaozitong screeningformicrornacombinationwithengineeredexosomesasanewtoolagainstosteosarcomainelderlypatients AT wangyanhong screeningformicrornacombinationwithengineeredexosomesasanewtoolagainstosteosarcomainelderlypatients AT yutao screeningformicrornacombinationwithengineeredexosomesasanewtoolagainstosteosarcomainelderlypatients AT wandaqian screeningformicrornacombinationwithengineeredexosomesasanewtoolagainstosteosarcomainelderlypatients |